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Abstract
Background:  Hyperammonemia, hypoglycemia, hepatopathy, and ventricular tachycardia are
common presenting features of carnitine-acylcarnitine translocase deficiency (Mendelian
Inheritance in Man database: *212138), a mitochondrial fatty acid oxidation disorder with a lethal
prognosis. These features have not been identified as the presenting features of mitochondrial
cytopathy in the neonatal period.
Case presentation: We describe an atypical presentation of mitochondrial cytopathy in a 2 day-
old neonate. She presented with a Reye-like syndrome episode, premature ventricular contractions
and ventricular tachycardia. Initial laboratory evaluation exhibited a large amount of 3-
methylglutaconic acid on urine organic acid analysis, mild orotic aciduria and a nonspecific abnormal
acylcarnitine profile. The evaluation for carnitine-acylcarnitine translocase deficiency and other
fatty acid oxidation disorders was negative. The patient later developed a hypertrophic
cardiomyopathy and continued to be affected by recurrent Reye-like syndrome episodes triggered
by infections. A muscle biopsy exhibited signs of a mitochondrial cytopathy. During the course of
her disease, her Reye-like syndrome episodes have subsided; however, cardiomyopathy has
persisted along with fatigue and exercise intolerance.
Conclusions: This case illustrates that, in the neonatal period, hyperammonemia and ventricular
tachycardia may be the presenting features of a lethal carnitine-acylcarnitine translocase deficiency
or of a mitochondrial cytopathy, associated with a milder clinical course. This association broadens
the spectrum of presenting phenotypes observed in patients with disturbed mitochondrial energy
metabolism. Also, the presence of 3-methylglutaconic aciduria suggests mitochondrial dysfunction
and mild orotic aciduria could potentially be used as a marker of mitochondrial disease.
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Background
Mitochondrial cytopathies are a heterogeneous group of
disorders that can affect almost all organ systems reflect-
ing ATP depletion. Neuromuscular disorders were the first
to be studied, and direct evidence of mitochondrial DNA
(mtDNA) abnormalities was demonstrated in 1988 [1,2].
However, only 6% of the patients suspected of having mi-
tochondrial disorders have been found to have mtDNA
point mutations or deletions [3]. Most pediatric mito-
chondrial disorders are caused by defects in nuclear genes
and with an autosomal recessive inheritance [4]. This case
of neonatal mitochondrial dysfunction presenting with
hyperammonemia and ventricular tachycardia expands
the clinical spectrum of these disorders.
Case presentation
We report the case of a 1 day-old neonate with unusual
presenting features of a mitochondrial cytopathy and a
unique clinical course. She was born at term after an un-
complicated pregnancy to healthy, unrelated parents of
Northern European descent with a negative family histo-
ry. On her first day of life, she was noted to be lethargic,
and was feeding poorly. Persistent hypoglycemia, hypo-
thermia and seizures precipitated her transfer to the neo-
natal intensive care unit. On physical exam she was found
to be a non-dysmorphic, term female. Birth weight was
3515 grams (80th centile), length was 48.6 cm (50th cen-
tile) and head circumference was 35 cm (75th centile). Sig-
nificant findings on her physical exam included a
distended abdomen with hepatomegaly and hypotonia.
Tests for bacterial and viral infections were ultimately neg-
ative. The patient was noted to have hypoglycemia (30
mg/dl) with a small amount of ketones in the urine. She
had an elevated ammonia level of 357 µmol/L (normal
range: 22–48), lactic acid of 10 mmol/l (normal range:
0.2–2), elevated transaminases with an alanine ami-
notransferase of 69 U/L (normal range: 10–25), an aspar-
tate aminotransferase of 162 U/L (normal range: 15–50),
and hypothermia with deteriorating neurological condi-
tion. She was subsequently treated with intravenous glu-
cose. Sodium benzoate, sodium acetate, and arginine
hydrochloride were administered intravenously to treat
her hyperammonemia that eventually responded twenty-
four hours after initiation of therapy. In view of her hyper-
ammonemia, she was placed on a protein-restricted diet
(2 g/kg/day) at 3 days of age. Her neurologic status im-
proved steadily after her hyperammonemia was control-
led. Brain MRI was reportedly normal.
Electroencephalogram demonstrated diffuse encephalop-
athy. Her initial presentation with hyperammonemia
prompted a genetics consult. Plasma amino acid analysis
showed an elevated alanine of 631 µmol/L (normal range:
141–343) with no other abnormalities. Measurement of
carnitine levels showed no evidence of carnitine deple-
tion. However tandem mass spectrometry of acylcarni-
tines revealed a slightly elevated propionylcarnitine of 1.4
µM (normal range:0–0.4 µM) that was not to the extent
seen in organic acidemias. Quantitative analysis of urine
organic acids by gas chromatography/mass spectrometry
exhibited elevated levels of 3-methylglutaconic (3-MGC)
acid of 121 mmol/mol of creatinine (normal range:0–8)
and 3-methylglutaric (3-MGR) acid of 33 mmol/mol of
creatinine (normal range:0–2) with a normal level of 3-
hydroxyisovaleric acid of 40 mmol/mol of creatinine
(normal range:0–39) making the diagnosis of type I 3-
MGC aciduria less likely. Her urine orotic acid was mildly
elevated at 81 nmoles orotic acid/mg creatinine (normal
range:<60 nmoles orotic acid/mg creatinine).
At 4 days of age, she developed premature ventricular con-
tractions that were immediately followed by sustained
ventricular tachycardia that eventually responded to treat-
ment with β-blockers. Initial work-up did not reveal any
evidence of a cardiomyopathy. A skin biopsy was per-
formed to rule out carnitine-acylcarnitine translocase de-
ficiency and other fatty acid oxidation disorders. At 10
days of age, the proband was noted to have a heart mur-
mur and an echocardiogram revealed at that time, hyper-
trophic cardiomyopathy with moderate left ventricular
hypertrophy and a left ventricular shortening fraction of
30%. Her special diet was discontinued prior to discharge
since the results of plasma amino acids, urine organic ac-
ids, and urine orotic acid did not support the possible di-
agnoses of a primary urea cycle disorder or organic
acidemia as the etiology of her hyperammonemia. Carni-
tine-acylcarnitine translocase deficiency or other type of
fatty acid oxidation disorder was suspected because of her
initial presentation. Once on full feeds, a trial off sodium
benzoate, sodium phenylacetate, and arginine resulted in
maintenance of her ammonium levels below 100 µmol/L.
The patient was discharged at sixteen days of age on full
breast milk feeds, and a β-blocker.
Fibroblasts were incubated with palmitate labeled with
deuterium and L-carnitine and fatty acid oxidation studies
with an in vitro probe were conducted. Normal levels of la-
beled intermediates were observed from C16 to C4 with-
out evidence for translocase deficiency or any other type
of fatty acid oxidation disorder. At two months of age, she
was mildly hypotonic on a follow up evaluation and the
diagnosis of a possible mitochondrial cytopathy was sus-
pected. Because of a suspicion of a possible mitochondrial
disorder, the activities of pyruvate dehydrogenase, pyru-
vate carboxylase, and mitochondrial respiratory chain en-
zyme activities (complexes II-IV) were tested in fibroblasts
with normal results. Ophthalmologic and audiologic
evaluations were normal. Her urinary organic acid profile
remained unchanged in the fasting and postprandial
states. Over a period of four years, the patient was admit-
ted several times for recurrent Reye-like syndrome epi-BMC Pediatrics 2002, 2 http://www.biomedcentral.com/1471-2431/2/12
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sodes triggered by viral illnesses and decreased oral intake.
Though one of these episodes was associated with cardiac
arrest at two years of age, she always responded well to
treatment without apparent neurological sequelae. At 11
months, there was a concern about possible failure to
thrive, nevertheless, her current growth and development
at seven years of age have been adequate. The proband has
developed a clinical course characterized by increasing
tolerance to fasting and illness without further episodes of
metabolic decompensation. At seven years of age, she has
exhibited fatigue, exercise intolerance and palpitations as
the main features of abnormal mitochondrial energy me-
tabolism. No episodes of sustained ventricular tachycar-
dia have been documented recently. Her cardiomyopathy
has improved and the results of her last echocardiogram
showed mild left ventricular hypertrophy and a left ven-
tricular shortening fraction of 50%.
Methods
Muscle biopsy
A muscle biopsy was performed at 30 months of age, dur-
ing a hospitalization for a Reye-like syndrome episode, to
further pursue the work-up of a mitochondrial disorder.
Cryostat sections of flash frozen muscle were stained with
hematoxylin and eosin, the modified Gomori trichrome
stain, and for succinate dehydrogenase, cytochrome c ox-
idase activity, reduced nicotinamide adenine dinucleotide
(NADH) dehydrogenase, and adenosine triphosphatase
(ATPase) activities at pH 4.3 and 4.6. Muscle was also
fixed in glutaraldehyde for electron microscopy.
Respiratory chain enzyme analysis
Respiratory chain enzymes were measured in 10% ho-
mogenates using previously described methods as fol-
lows: NADH dehydrogenase [5], NADH cytochrome c
reductase [5], succinate dehydrogenase [6], succinate cy-
tochrome c reductase [6], cytochrome c oxidase [7], and
citrate synthase [8]. Enzyme activities were expressed as
µmol/min/g of wet weight tissue.
MtDNA mutation analysis
MtDNA from blood and skeletal muscle was extracted and
analyzed for mtDNA point mutations, deletions or dupli-
cations by multiplex polymerase chain reaction-allele spe-
cific oligonucleotide (PCR/ASO) dot blot hybridization
and Southern blot analysis. Quantitative evaluation of
mtDNA content was performed in skeletal muscle by
Southern blot and Real Time quantitative PCR analyses
[9]. To look for unknown mtDNA mutations, the entire
mitochondrial genome was screened by temporal temper-
ature gel electrophoresis (TTGE) on mother/child pair,
followed by sequencing of the DNA fragments that exhib-
ited different banding patterns between mother and child.
Results
Muscle biopsy
Gomori trichrome stain revealed ragged red fibers (Figure
1). Electron microscopy showed concentric arrangements
of cristae with rare dense bodies, excess glycogen and fat
deposition, and focal rare Z-disc streaming (Figure 2).
Enzyme studies
The activity of the mitochondrial respiratory chain en-
zymes, although mostly below the normal mean, was
within the normal range in skeletal muscle with moderate
increase (52%) in the activity of citrate synthase suggest-
ing mitochondrial proliferation (Table 1).
MtDNA mutation analysis by PCR/ASO dot blot hybridiza-
tion and Southern blot
MtDNA common point mutations (MELAS A3243G and
T3271C, MERRF A8344G and T8356C, NARP T8993G
and T8993C, cardiomyopathy G8363A, and LHON
G11778A, G3460A, T14484C, and G14459A), deletions,
or duplications, were not detected in blood or skeletal
muscle. A cardiomyopathy screen was negative for the 6
point mutations in mtDNA reported in patients with car-
diomyopathy: A3243G, C3303T, A4269G, A4300G,
G8363A and T9997C.
Quantitative mtDNA analysis
Quantitative evaluation of mtDNA content in patient's
muscle specimen revealed no evidence of mtDNA deple-
tion.
TTGE and MtDNA sequencing
A homoplasmic T3197C nucleotide substitution was de-
tected in this patient's blood and muscle and it was also
detected on the proband's mother and on two half sib-
lings. Both mother and child were found to have two com-
mon polymorphisms in homoplasmic state, G185A and
A73G. An obvious difference was found in the D-loop re-
gion where A189G was present in the proband in a near
homoplasmic state and homoplasmic wild type A189 was
present in the proband's mother. A novel germline varia-
tion, 568–573 insCCCCC, was present in both mother
and the proband. Four mtDNA regions that did not exhib-
ited any difference between mother and proband's mtD-
NA on TTGE analysis (nucleotide position 3085 to 3758,
4013 to 4508, 8295 to 8600, and 9827 to 10286) were se-
quenced. The results confirmed the presence of T3197C
polymorphism in both mother and the proband. No oth-
er mutations in these regions, including the 6 point muta-
tions reported in patients with cardiomyopathy as stated
above, were detected.BMC Pediatrics 2002, 2 http://www.biomedcentral.com/1471-2431/2/12
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Discussion
Reye-like syndrome episodes
Reye syndrome, a disorder of unknown cause, is charac-
terized by acute encephalopathy and fatty degeneration of
the liver and it is usually characterized by a history of pre-
ceding viral illness or the use of aspirin during viral infec-
tions [10]. Many children with metabolic disorders
present with Reye-like syndrome episodes, usually at a
young age and/or with a positive past or family history
suspicious for an inborn error of metabolism [11]. It has
been reported as a presenting sign of type I 3-MGC aci-
duria and in a few cases of mitochondrial cytopathies in
older children [12,13]. However in the neonatal period, a
Reye-like episode is not a typical presenting feature of a
mitochondrial cytopathy.
Cardiac involvement in mitochondrial diseases
Inborn errors of mitochondrial fatty acid oxidation
should be considered in infants with conduction defects
or ventricular tachycardia. In 24 children with inherited
disorders of fatty acid oxidation, conduction defects or ar-
rhythmias were the predominant presenting feature [14].
Arrhythmias in association with hepatomuscular symp-
toms and hyperammonemia have also been demonstrat-
ed in cases of carnitine-acylcarnitine translocase
deficiency whose presenting features also include neona-
tal distress, convulsions, hypoglycemia, hypoketonemia,
intermittent dicarboxylic aciduria, hypothermia, apnea,
neurological deterioration, and hypocarnitinemia with
grossly elevated acylcarnitines [15]. The accumulation of
arrhythmogenic metabolites of fatty acids, such as long
chain acylcarnitines, may be responsible for the observed
lethal cardiac defects. Cardiac conduction disturbance has
also been recognized in the mitochondrial cytopathy,
Kearns-Sayre syndrome (Mendelian inheritance in Man
database *530000), characterized as progressive external
ophthalmoplegia and retinopathy [16]. Clinical manifes-
tations of cardiac disease occur in 57% of patients with
Figure 1
Gomori trichrome stain of skeletal muscle. Gomori trichrome stain of skeletal muscle reveals ragged red fibers (arrow).BMC Pediatrics 2002, 2 http://www.biomedcentral.com/1471-2431/2/12
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Figure 2
Electron microscopy of skeletal muscle. Abnormal concentric arrangements of cristae (arrow), with rare dense bodies 
can be seen. Notice excess glycogen and fat deposition which are features evocative of a mitochondrial myopathy. Focal Z-disc 
streaming can be seen.BMC Pediatrics 2002, 2 http://www.biomedcentral.com/1471-2431/2/12
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Kearns-Sayre syndrome [17]. The complete AV block in
Kearns-Sayre syndrome may also be associated less com-
monly with ventricular tachycardia, torsade de pointes
and ventricular fibrillation as the ultimate and often fatal
stage of the condition [18]. However, to our knowledge,
ventricular tachycardia as a presenting feature has not
been described in the context of mitochondrial cytopa-
thies in the neonatal period.
Causes of 3-MGC aciduria in children
3-MGC aciduria is a rare hereditary organic aciduria char-
acterized by increased urinary excretion of 3-MGC and 3-
MGR acids. At least 4 distinct clinical forms associated
with 3-MGC aciduria have been described [19]. Type I 3-
MGC aciduria (Mendelian Inheritance in Man database
*250950) due to 3-MGC CoA hydratase (EC 4.2.1.18) de-
ficiency has a relatively benign clinical course including
speech delay and macrochephaly; type II 3-MGC aciduria
(Barth syndrome) (Mendelian Inheritance in Man data-
base *302060) has a clinical picture that includes cardio-
myopathy, recurrent infections, neutropenia, short stature
and normal cognitive function and is caused by mutations
in the tafazzin gene (G4.5) [20]; type III 3-MGC aciduria
(Costeff optic atrophy syndrome) (Mendelian Inheritance
in Man database *258501) was described in patients of
Iraqi-Jewish origin with bilateral optic atrophy accompa-
nied in some by movement disorders and caused by mu-
tations in the OPA3 gene [21,22]; and type IV 3-MGC
aciduria (Mendelian Inheritance in Man database
*250951) presents with moderate to severe neurological
disease, cardiac, ophthalmic, hepatic, and renal symp-
toms and it has been associated with mitochondrial disor-
ders (Pearson syndrome, mitochondrial DNA depletion)
or multiple respiratory chain defects [23–26]. This group
does not have a defined primary biochemical or molecu-
lar defect. Our patient would fit in this latter clinically het-
erogeneous group although the degree of elevation of 3-
MGC seen in other cases could be as high as 600 mmol/
mol of creatinine. Barth syndrome, a cause of 3-MGC aci-
duria and cardiomyopathy, would be an unlikely diagno-
sis in our patient primarily due to absence of symptoms in
female carriers secondary to presumed skewing of X-inac-
tivation and lack of growth retardation and neutropenia.
We suspect that her organic aciduria is associated with mi-
tochondrial dysfunction. It has been speculated that an
abnormality of translocation of 3-MGC acid across the
mitochondrial membrane may be the source of 3-MGC
aciduria in these patients [23]. The link between 3-MGC
aciduria and mitochondrial dysfunction may involve fail-
ure of mitochondrial uptake of 3-MGC acid or potentially
defective ubiquinone biosynthesis leading to increased
levels of mevalonate in the mevalonate shunt pathway
with subsequent increased synthesis of 3-MGC acid [27].
MtDNA mutation analysis
Although there is no direct proof of a respiratory chain
(RC) defect in our patient, mitochondrial disorders can-
not be ruled out, as normal RC activities have been occa-
sionally reported in muscle samples from clinically
affected patients with proven mtDNA mutations or muta-
tions in nuclear genes that impact mitochondrial function
[28–30]. Respiratory chain activity studies on endomyo-
cardial biopsy would be helpful. Since no primary delete-
rious mtDNA mutation has been found in the proband
and she was born to healthy parents with unremarkable
family history, we hypothesize that the etiology of her mi-
tochondrial dysfunction could reside in a still unidenti-
fied nuclear gene defect; although secondary
mitochondrial dysfunction caused by an unknown in-
born error of metabolism cannot be excluded completely.
At the present time, the T3197C nucleotide substitution is
considered a polymorphism and it is not thought to have
pathogenic significance by itself [31]. Although most
pathogenic mutations are heteroplasmic, many homo-
plasmic mutations have been reported to have synergistic
effects in the presence of other primary mutations [32,33].
The only difference in mtDNA between the affected child
and the asymptomatic mother is the A189G mutation in
the hypervariable D-loop region. The A189G has been re-
ported as a polymorphism in Mitomap database [34].
Whether this alteration would affect mtDNA replication
or transcription is not known. A remarkable finding was
Table 1: Respiratory chain analysis of patient's skeletal muscle tissue
Enzyme Complex Activity 
(µmol/min-1/g-1)
Normal reference mean ± 1 SD
Cytochrome c oxidase IV 2.56* (2.8 ± 0.52)
Succinate cytochrome c reductase II + III 0.55 (0.7 ± 0.23)
NADH cytochrome c reductase I + III 1.44 (1.02 ± 0.38)
NADH dehydrogenase I 29.32 (35.48 ± 7.07)
Citrate synthase 15.01 (9.88 ± 2.55)
Succinate dehydrogenase II 1.15 (1 ± 0.53)
NADH = reduced nicotinamide adenine dinucleotide * Data represent the mean of 2 independent analyses on different muscle homogenatesBMC Pediatrics 2002, 2 http://www.biomedcentral.com/1471-2431/2/12
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the novel 568–573 insCCCCC, present in both mother
and proband. This region contains a stretch of 6 cytosines
(C's) in the wild type. The insertion of 5 C's results in a
long polyC tract. The polyC tract is located next to the mi-
tochondrial transcription factor 1 (mtTF1) binding site
and the major H-strand promoter sequence. It is not clear
if the length of this poly C stretch would influence pro-
moter activity or mtTF1 binding, thus, the transcription of
mitochondrial RNA. Further investigations are necessary
to define the clinical significance of the homoplasmic
mtDNA alterations found in the proband and to know
whether they may act as secondary mutations, synergisti-
cally with a primary defect (either nuclear or mitochondri-
al) that could affect the mitochondrial function and result
in this clinical condition.
Orotic aciduria and abnormal acylcarnitine profile as po-
tential markers of mitochondrial disease
It has been reported before that an increased excretion of
orotate in sick children may not be uncommon and that a
positive allopurinol load test may indicate unrecognized
mitochondrial disease, making orotic acid as a potential
marker of mitochondrial dysfunction [35]. A potential
link between mitochondrial cytopathies and urea cycle
dysfunction has also been suggested by the findings of hy-
pocitrullinemia in patients with neurogenic weakness,
ataxia and retinitis pigmentosa (NARP) syndrome (Men-
delian Inheritance in Man database *551500) caused by a
T8993G mutation in mtDNA that triggers ATPase defi-
ciency [36,37]. It was hypothesized that the NARP muta-
tion would cause complex V deficiency in the small
intestine as well, thus reducing the availability of mito-
chondrial ATP required for citrulline synthesis. The pres-
ence of mild increase in the urinary excretion of orotic
acid in this patient could also suggest mitochondrial dys-
function, convalidating this hypothesis.
It has been noticed that if a patient is suspected of having
a mitochondrial disease, abnormal carnitine esters may
help with the diagnosis, [38] and abnormal acylcarnitine
profiles do not exclusively indicate fatty acid oxidation
disorders [39]. Although the abnormal carnitine ester
present in the proband is elevated in organic acidemias
and is not usually present in mitochondrial cytopathies,
we speculate that due to compromised ATP synthesis, sec-
ondary alterations may be generated in these patients by
changes in mitochondrial protein synthesis, decrease in
Krebs cycle intermediates and increased free radical for-
mation, that could be responsible for a secondary impair-
ment of mitochondrial biotin dependent carboxylases,
but further elucidation is necessary before we could arrive
to a conclusion in this regard.
Conclusions
Although alterations in mitochondrial morphology do
not necessarily reflect well-defined mitochondrial disor-
ders and we cannot completely exclude the possibility of
an unknown metabolic disorder with secondary mito-
chondrial dysfunction, we speculate that all the clinical,
biochemical and histological features in the proband can
be attributed to disturbed mitochondrial energy metabo-
lism. We suspect that this proband's 3-MGC aciduria re-
flects a defect in mitochondrial energy metabolism and
that her mild orotic aciduria may be a nonspecific marker
of mitochondrial dysfunction. Mitochondrial cytopathies
are a group of disorders that are clinically heterogeneous
with variable forms of presentation. We conclude that
ventricular tachycardia in association with a Reye-like syn-
drome episode in the neonatal period may suggest mito-
chondrial dysfunction, and that the investigation of a
mitochondrial cytopathy may be warranted in this clinical
scenario. Our patient's neonatal presentation and relative-
ly mild clinical course broadens the heterogeneous spec-
trum of clinical phenotypes associated with altered
mitochondrial energy metabolism.
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